This document describes the design, fabrication, and evaluation of a novel sustained release drug delivery system using rosuvastatin pharmacosomes. Rosuvastatin was complexed with lecithin phospholipids to form pharmacosomes via a hand shaking method. The pharmacosomes showed improved solubility, drug loading efficiency, and sustained release properties compared to pure rosuvastatin. In vivo studies in rats demonstrated the pharmacosomes more effectively lowered cholesterol and triglyceride levels over longer periods compared to standard rosuvastatin treatment. Thus, the rosuvastatin pharmacosomes represent a promising sustained release drug delivery system with benefits like enhanced bioavailability and reduced dosing.
Introduction to Higuchi plots for tablet dissolution
Dissolution, Dissolution Models, Higuchi Plot
Presented by
Mohamed Omar Mahmoud
Department of Pharmaceutics
This slide share includes the introduction about smedds, difference between emulsion and smedd and sedds and smedds, composition and its formulation aspects.
CLINICAL SIGNIFICANCE OF BIOEQUIVALENCE STUDIES, BIOEQUIVALENCE, REASONS TO PERFORM BIOEQUIVALENCE STUDIES , NEED FOR BIOEQUIVALENCE STUDIES, IMPORTANCE OF BIOEQUIVALANCE STUDIES, DETERMINATION OF BIOEQUIVALENCE OF A DRUG PRODUCT, CLINICAL SIGNIFICANCE.
Introduction to Higuchi plots for tablet dissolution
Dissolution, Dissolution Models, Higuchi Plot
Presented by
Mohamed Omar Mahmoud
Department of Pharmaceutics
This slide share includes the introduction about smedds, difference between emulsion and smedd and sedds and smedds, composition and its formulation aspects.
CLINICAL SIGNIFICANCE OF BIOEQUIVALENCE STUDIES, BIOEQUIVALENCE, REASONS TO PERFORM BIOEQUIVALENCE STUDIES , NEED FOR BIOEQUIVALENCE STUDIES, IMPORTANCE OF BIOEQUIVALANCE STUDIES, DETERMINATION OF BIOEQUIVALENCE OF A DRUG PRODUCT, CLINICAL SIGNIFICANCE.
Objective: The purpose of the current research work was to study effect of formulation variables in a statistical way for the SR formulations of Valsartan sodium. Methods: Valsartan sodium is an antihypertensive agent angiotensin‒II receptor blocker belongs to BCS class‒III agent. SR tablet formulations of Valsartan sodium were formulated using variable quantities of HPMCK100M and Xanthan Gum by direct compression method. quantities of polymers was chosen as independent variables, X1 and X2 respectively whereas, time required for dissolution 10%(t10%), 50%(t50%), 75%(t75%) and 90%(t90%) of drug from formulation were chosen as dependent variables. 9 formulations were prepared and evaluated for various pharmacopoeial tests. Results: The results reveals that all formulations were found to be with in the acceptable limits and release rate profiles of all formulations were fitted to kinetic models. The statistical parameters were determined. Polynomial equations were developed for dependent variables. Validity of them was checked by countercheck formulations (C1 ,C2 ). According to SUPAC guidelines, formulation (F4) containing mixture of 12% HPMCK100M and 16% Xanthan gum, was found to be identical formulation (dissimilarity factor f1 =1.763, similarity factor f2 =86.747 & No significant difference, t=0.0478) to marketed product (VALZAAR). Conclusion: Formulation F4 follows First order kinetics, Non‒Fickian Diffusion Anomalous Transport. (n=0.826).
If revisions are requested, the authors need to address the reviewer's comments and make the necessary changes to the paper. The revised paper is then resubmitted to the journal or conference for another round of review or evaluation of the journalism research paper.
Formulation and evaluation of omeprazole floating tabletsmedicinefda
formulation and evaluation of omeprazole floating tablets, literature review and plan of work ,methods results and discussion,conclusion sample ppt http://www.medicinefda.com/
Stability indicating method development and validation for the simultaneous e...pharmaindexing
Stability indicating method development and validation for the simultaneous estimation of rabeprazole sodium and ketorolac tromethamine in bulk and synthetic mixture by RP-HPLC
The Metformin HCL Gastroretentive Floating Sustained released Tablet is formulated by the Wet Granulation technique. This Tablet is containing both Effervescent as well as Non Effervescent system. The HPMC K 100 Swellable polymer is responsible for the Floating. (Non Effervescent system) and The Sodium Bicarbonate is responsible for
the effervescent system. A combination of HPMC K 100 and Xanthum Gum shows better sustained release activity. The Prepared Gastroretentive Floating Sustained released Tablet is Evaluated In terms of bulk density, tapped density, angle of repose, Carr’s Index and, weight variation test, friability test and in vitro study, Total Floating Time. The result associated in Optimized batch is good to Satisfactory and having a good free flowing property. The weight variation and friability these values are within the pharmacopeia limit. The in vitro Dissolution studies shows Maximum percentage of release of drug (99.25) with in end of 8 Hours.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Colonic and anorectal physiology with surgical implications
Pharmacosome of rosuvastatin
1. “DESIGN, FABRICATION AND EVALUATION OF
PHARMACOSOME OF ROSUVASTATIN- A NOVEL
SUSTAINED RELEASE DRUG DELIVERY
SYSTEM”
Under Guidance of
PROF. DR. TAPAS KUMAR PAL
Presented by
ABHISHEKH PODDER
M.PHARM 4th SEMESTER
REG NO.-12277231002
ROLL NO.-27720312001
PHARMACEUTICS
NSHM KNOWLEDGE CAMPUS- KOLKATA ,
GROUP OF INSTITUTIONS
2. INTRODUCTION
• Pharmacosomes are lipid based vesicular drug delivery
system that are elaborated as the amphiphilic colloidal
dispersions of drugs having a covalent bonding with
phospholipids.
• Depending upon the chemical structure of the drug-
phospholipid complex, they may exist as ultrafine vesicular,
micellar or hexagonal aggregates.
3. MERITS OF PHARMACOSOME
• Enhancement in bioavailability of poorly water soluble as well
as poorly lipophilic drugs.
• Entrapment efficiency is not only high but also predetermined.
• Pharmacosome can mobilise biomembranes enabling a better
transfer of active ingredient.
• Pharmacosome shows better stability profile due to chemical
bonding in between phospholipid and drug.
4. VESICULAR
SYSTEM
ISSUES ENCOUNTERED ADVANTAGE OF
PHARMACOSOME
LIPOSOME 1.Expensive
2.Degradation by oxidation
3.Lack of purity of natural
phospholipids
4.Chances of leaching of drug
1.Cheaper
2.Oxidation resistant
3.Pure natural
phospholipid not needed
4.Covalent linkage
prevents drug leakage.
NIOSOME 1.Time consuming prepn.
2. Comparatively less efficient
3. Instability
1.Less time consuming
prepn.
2.More efficient
3.More stable
TRANSFEROSOME 1.Expensive,
2.Chemical instability
1.Cheap
2.Chemically stable
PHARMACOSOMES DIFFERS FROM LIPOSOME, NIOSOME
AND TRANSFEROSOME
5. CRITERION OF DRUG FOR DEVELOPMENT OF
PHARMACOSOME
A drug possessing a free carboxyl group or an active hydrogen
atom (-NH2, -OH, -COOH) can be esterified with or without a
spacer chain to the PHOSPHOLIPID molecule
Molecular structure of Phosphatidylcholine – a Phospholipid
6. MATERIALS OF PHARMACOSOME
• Drug – Rosuvastatin Calcium ( BCS class II drug)
Appearence: White amorphous powder
Melting point: 122C
Solubility: Sparingly soluble in water and methanol and slightly soluble
in ethanol.
(Bioavailability 20%)
• Phospholipid- Lecithin Soya (30 %)
• Appearance: Yellowish to brown powder
7. OBJECTIVES OF PRESENT STUDY
• To identify, asses purity & strength of Rosuvastatin calcium
• To prepare Pharmacosome of Rosuvastatin .
• To evaluate the Physicochemical charecter of Pharmacosomes.
• To evaluate increase of solubility and drug release profile.
• To evaluate increase of sustained profile of drug release and
drug diffusion.
• To assess improvement in patient compliance by dose
reduction.
• To make more efficacious & economic anti-hyperlipidemic
therapy.
• Stability study of optimized formulation.
8. PREPARATION OF PHARMACOSOME OF ROSUVASTATIN
(1:1MOLAR RATIO) BY HAND SHAKING METHOD
ACIDIFICATION OF ROSUVASTATIN CALCIUM:
Rosuvastatin in chloroform
Extraction
Rosuvastatin
Calcium
Rosuvastatin
acidification by
1(N) HCL
Shake-flask method
Measured residual drug as
Rosuvastatin calcium, remaining
in aqueous solution – 0.22%.
9. FLOW SHEET DIAGRAM OF ROSUVASTATIN(RSV)-PC COMPLEX
IN LABORATORY:
Rosuvastatin dissolved in
Chloroform (1 mole)
Phosphatidylcholine
dissolved in
Dichloromethane (1
mole)
Mixed well in a 250 ml round bottom flask and reflux for 3hrs at 45c
Transferred into a beaker for solvent
evaporation
Thin film is deposited on the walls of beaker
Vaccum drying in a vaccum dryer for 24hrs at 45c and 15
lb pressure
Collect the dried residues and placed in vaccum desiccator overnight
10. RESULTS
Calibration curve of Rosuvastatin
calcium in water
Calibration curve of Rosuvastatin
calcium in pH6.8 Phosphate buffer
y = 0.0378x
R² = 0.9992
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
0 5 10 15 20
concentration(µg/ml)
Absorbance
y = 0.032x
R² = 0.999
0
0.1
0.2
0.3
0.4
0.5
0.6
0 5 10 15 20
11. EVALUATION OF ROSUVASTATIN(RSV)-PC COMPLEX :
36 mg Rosuvastatin-Pc complex equivalent to10 mg Rosuvastatin
calcium accurately weighed
Added into a conical flask with 100ml of pH 6.8 phosphate buffer
Conical flask stirred continuously for 24 hr on a shaker incubator
Drug content
50 ml RSV-PC complex solution
Suitable dilutions were made
and measured at 242 nm uv
spectrophotometrically
40ml RSV-PC complex
solution with 40ml octanol
Solubility study
Aqueous layer and octanol
layer measured at 242 nm uv
spectrophotometrically
Shake-flask method
Diluted with 50ml pH 6.8 buffer
Membrane filtration
12. Code Drug content (%)* Drug loading(%)*
F1 91.1±0.64 25.3± 0.19
F2 94.4± 0.61 26.2± 0.13
F3 92.7± 0.62 25.8± 0.15
F4 90.4± 0.82 25.1±0.14
F5 91.9± 0.49 25.5± 0.14
F6 92.2± 0.63 25.6±0.11
*mean± S.D, n=3 ,(F1- F6)= Pharmacosome of Rosuvastatin
Drug content study:
13. Comparative Solubility study between Pharmacosome of
Rosuvastatin and pure drug Rosuvastatin Calcium
Code
Solubility in aquous
layer(µg/ml)*
Solubility in octanol
layer(µg/ml)* Log P
F1 91.12± 1.24 42.01±0.62 -0.33
F2 92.37± 1.94 41.70±1.13 -0.34
F3 90.79±0.78 44.36±0.71 -0.31
F4 83.06±1.33 46.56±1.68 -0.25
F5 86.42±1.58 45.25±0.87 -0.28
F6 87.89±1.77 44.66±1.12 -0.30
D1 11.0± 0.35 192.62± 1.59 1.24
*mean± S.D, n=3 ,(F1- F6)= Pharmacosome of Rosuvastatin, D1= Pure drug
Rosuvastatin Calcium
18. X Ray Diffraction(XRD)
A
B
C
A) XRD of Pure Rosuvastatin Calcium , B) XRD of lecithin soya (30%),
C) XRD of Pharmacosome of Rosuvastatin
19. Comparative % Cumulative dissolution release of Pharmacosome
formulations at different time with Pure Rosuvastatin Calcium
0
20
40
60
80
100
120
0 200 400 600 800 1000 1200 1400 1600
F1
F2
F3
F4
F5
F6
pure Rsv ca
Time in minutes
%Cumulativerelease
20. 0.00
20.00
40.00
60.00
80.00
100.00
120.00
0 200 400 600 800 1000 1200 1400 1600
F1 F2 F3 F4 F5 F6 pure Rsv Ca
Time in minutes
%cumulativediffusion
Comparative % Cumulative diffusion study of Pharmacosome formulations
at different time with Pure Rosuvastatin Calcium
(Modified Franz diffusion cell using egg membrane)
21. Group Model
Gr. 1 Administered vehicle(0.1% Na CMC suspension,orally) and
served as Normal control
Gr. 2 Administered Triton X 100 and served as Positive
control(200mg/kg b.w, i.p)
Gr. 3 Administered daily dose of Rosuvastatin calcium(10mg/kg b.w
i.p)+ Tritron X 100 (200mg/kg b.w, orally)
Gr.4 Administered once single dose of Pharmacosome of
Rosuvastatin (36mg/kg b.w, orally) + Tritron X 100 (200mg/kg
b.w, i.p)
Comparison of in vivo efficiency of pharmacosome with standard drug
Rosuvastatin calcium as lipid lowering agent to reduce blood cholesterol
level
Statistical Analysis: All values are expressed as Mean± SEM for six animals
in each group using one way analysis of variance (ANOVA) followed by
Dunnett's Multiple Comparison Test .
22. Comparative effect of pharmacosome of Rosuvastatin and standard
drug Rosuvastatin Calcium in Triglycerides(TG) levels
0
20
40
60
80
100
120
140
160
180
200
normal control positive control Rosuvastatin calcium+
tritron
Rosuvastatin
pharmacosome+ tritron
Triglycerideslevel(mg/dl)
Group
24 hr (TG)
48 hr (TG)
* *
*# *# *# *#
P value: P<0.0001***, P < 0.01* when compared with normal control,
P value: P<0.0001###, P < 0.01# when compared with positive control
23. Comparative effect of pharmacosome of Rosuvastatin and standard
drug Rosuvastatin Calcium in Total Cholesterol (TC)levels
0
20
40
60
80
100
120
140
160
normal control positive control Rosuvastatin calcium+
tritron
Rosuvastatin
pharmacosome+ tritron
TotalCholesterol(mg/dl)
Group
24 hr( TC)
48 hr (TC)
*
*
*#
*#
*#
*#
P value: P<0.0001***, P < 0.01* when compared with normal control,
P value: P<0.0001###, P < 0.01# when compared with positive control
24. Comparative effect of pharmacosome of Rosuvastatin and standard
drug Rosuvastatin Calcium in HDL- Cholesterol levels
0
5
10
15
20
25
30
35
40
45
normal control positive control Rosuvastatin calcium+
tritron
Rosuvastatin
pharmacosome+ tritron
HDLCholesterol(mg/dl)
Group
24 hr (HDL) 48 hr (HDL)
* #
*#
*#
*#
*
*
P value: P<0.0001***, P < 0.01* when compared with normal control,
P value: P<0.0001###, P < 0.01# when compared with positive control
25. 0
2
4
6
8
10
12
normal control positive control Rosuvastatin calcium+
tritron
Rosuvastatin
pharmacosome+ tritron
AI
Group
24 hr (AI)
48 hr (AI)
Comparative effect of pharmacosome of Rosuvastatin and
standard drug Rosuvastatin Calcium in Atherogenic Index (
TC/HDL-C):
26. Histopathology study of liver
A
B
C D
A) Normal control , B) Positive control, C) Standard drug treated,
D) Pharmacosome treated
27. Stability study of optimized formulation at ICH condition
(40C and 75%RH)
Code Drug Content (%) Drug loading (%)
F3(Initial) 92.7± 0.62 25.80± 0.15
F3 (After 2
month) 91.11±0.47 25.29±0.10
28. CONCLUSION
• This Pharmacosome of Rosuvastatin may be of potential use for
improving bioavailability.
• Pharmacosome seem to be potential candidate as an oral
sustained drug delivery system in this era of novel and sustained
drug delivery systems.
• Pharmacosome of Rosuvastatin are expected to improve the
patient compliance, form better dosage regimen, dose
reduction and provide optimum maintenance therapy to
Hyperlipedimic patients.